DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE (R)), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC)-MedSci.cn

DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE (R)), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC)

Gadgeel, SM; Al-Mondhiry, J; Ahn, MJ; Kim, SW; Paz-Ares, L; Prenen, H; Boyer, M; Alvarez, JGB; Solomon, B; Huang, S; Minocha, M; Kistler, M; Sadraei, NH

ANNALS OF ONCOLOGY, 2022; 33 (7): S1255

科室
- - 订阅+
  - 更多科室
工具
服务